Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality? Journal Article
| Authors: | Krantz, B. A.; O'Reilly, E. M. |
| Article Title: | Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality? |
| Abstract: | Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development. © 2017 American Association for Cancer Research. |
| Keywords: | cancer survival; sorafenib; erlotinib; placebo; drug efficacy; patient selection; gemcitabine; colorectal cancer; gastrointestinal stromal tumor; imatinib; stem cell factor receptor; unindexed drug; ca 19-9 antigen; carcinoembryonic antigen; epidermal growth factor receptor; epidermal growth factor receptor 2; lung cancer; cetuximab; tumor marker; cancer therapy; prediction; cancer resistance; panitumumab; drug mechanism; bioassay; pancreas adenocarcinoma; stomach cancer; clinical decision making; estrogen receptor; progesterone receptor; trastuzumab; k ras protein; b raf kinase; circulating tumor cell; disease activity; ribonucleotide reductase; minimally invasive procedure; exosome; dalotuzumab; crizotinib; dabrafenib; trametinib; afatinib; mk 0752; rucaparib; human; priority journal; article; circulating tumor dna; ceritinib; gemcitabine elaidate; solid malignant neoplasm; co 1 01 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 24 |
| Issue: | 10 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-05-01 |
| Start Page: | 2241 |
| End Page: | 2250 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-16-3169 |
| PROVIDER: | scopus |
| PMCID: | PMC5955785 |
| PUBMED: | 29269376 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 July 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work